[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581430":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":7,"responsibleParty":14,"collaborators":7,"id":18,"slug":19,"hasResults":20,"nctId":21,"briefTitle":22,"officialTitle":23,"acronym":7,"eligibilityCriteria":24,"healthyVolunteers":20,"sex":25,"minAge":7,"maxAge":7,"enrollmentInfo":26,"targetDuration":29,"studyType":30,"phases":7,"briefSummary":31,"conditions":32,"keywords":34,"overallStatus":38,"whyStopped":7,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":7},{"fullName":5,"class":6},"Chengdu University of Traditional Chinese Medicine","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"QIqi Wang","CONTACT","086-15184495605","wangqiqi_czyfy@163.com",{"type":15,"investigatorFullName":16,"investigatorTitle":17,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Chunshui He","Chief Physician","100581430","effect-of-anticoagulant-and-antiplatelet-drug-intervention-on-postoperative-major-adverse-events-in-patients-with-padphase-ii-100581430",false,"NCT06850207","Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with PAD：Phase II","Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with Peripheral Arterial Disease：Phase II","Inclusion Criteria:\n\n* 1\\. History of PAD, or a history of intermittent claudication with an ankle\u002Fbrachial blood pressure ratio \\\u003C 0.9, or angiography-confirmed significant peripheral arterial stenosis (≥50%).\n\n  2\\. Underwent endovascular treatment for aortoiliac, femoral, popliteal, or infrapopliteal arteries.\n\n  3\\. No restrictions on endovascular treatment methods, including all internationally recognized devices and techniques used in real-world practice.\n\n  4\\. Agreed and signed the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. \\*\\*Patients with a history of stroke within the past month\\*\\* or a history of hemorrhagic or lacunar stroke.\n\n  2\\. Patients with a known ejection fraction \\\u003C 30% or severe heart failure with Class III\u002FIV symptoms.\n\n  3\\. Patients with non-cardiovascular diseases associated with poor prognosis(e.g., metastatic cancer) or interventions that increase the risk of adverse events in the study.\n\n  4\\. Patients with a history of allergies or known contraindications to drugs such as rivaroxaban or aspirin.\n\n  5\\. Patients with any known liver disease associated with coagulation disorders. 6. Pregnant or breastfeeding women, or women of childbearing potential who are sexually active and not using effective contraception.\n\n  7\\. Patients with known contraindications to any study-related procedures.","ALL",{"count":27,"type":28},6000,"ESTIMATED","12 Months","OBSERVATIONAL","This study is a multicenter, prospective, observational research project. It is anticipated to enroll a total of 6,000 patients between February 1, 2025, and January 31, 2028 (with completion of one-year postoperative follow-up by January 31, 2029). Patients will be grouped according to different combinations of anticoagulant and antiplatelet drugs used postoperatively for PAD. The types, dosages, and duration of postoperative anticoagulant and antiplatelet drug use will be recorded. Follow-up assessments will be conducted at 1 month, 6 months, and 12 months postoperatively to document the occurrence of Major Adverse Cardiovascular Events (MACE) and Major Adverse Limb Events (MALE) in the enrolled patients.",[33],"Peripheral Arterial Disease(PAD)",[35,36,37],"peripheral arterial disease","Anticoagulant and Antiplatelet Drug","Adverse Events","NOT_YET_RECRUITING","2025-02-23",{"date":41,"type":42},"2025-02-27","ACTUAL",{"date":44,"type":28},"2025-02-28",{"date":46,"type":28},"2029-01-31",{"name":5,"class":6}]